Secondary Marketplace / Trade Private Companies / Buy and Sell Zenas BioPharma Stock
Zenas BioPharma Zenas BioPharma Stock
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies similar to Zenas BioPharma before its IPO, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Zenas BioPharma Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Zenas BioPharma Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
Funding Round Details are not yet available for this company.
Company Details
Zenas BioPharma is a biopharmaceutical company that aims to develop inflammatory and immunology therapies. The company has a mission to address the unmet needs of patients who experience autoimmune and rare diseases by discovering differentiated approaches to current treatments. The company's lead product candidate is obexelimab, which is a bifunctional monoclonal antibody that was designed to inhibit B-cell activity. Zenas BioPharma was founded in 2019 by Lonnie Moulder Jr. and is headquartered in Waltham, MA.
Founded
2020
Post-Money Valuation 3
--
Total Funding
--
LFR Price per Share
$xx.xx
Last Funding Share Class
--
Zenas BioPharma Stock FAQs
To buy and sell Zenas BioPharma stock
Can you buy Zenas BioPharma stock?
You can no longer buy Zenas BioPharma stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy Zenas BioPharma stock?
You can no longer buy Zenas BioPharma stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell Zenas BioPharma stock?
You can no longer sell stock of Zenas BioPharma on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell Zenas BioPharma stock?
You can no longer sell stock of Zenas BioPharma on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about Zenas BioPharma stock
Is Zenas BioPharma a public company?
Zenas BioPharma is now a public company traded on NASDAQ with ticker ZBIO.
What is Zenas BioPharma’s stock price?
The stock price of Zenas BioPharma is not currently available.
What is Zenas BioPharma’s stock ticker symbol?
The ticker symbol of Zenas BioPharma is ZBIO.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Zenas BioPharma Investors Also Invested in These Private Companies

Tellus Bioventures
Pivotal Bioventure Partners
Quantum Ventures
Federated Hermes
Superstring Capital Management
Fairmount Funds Management
Wuxi Biologics
Lepu Biopharma

Leadership & Board

Leadership

Lonnie Moulder Jr.
Founder & Chief Executive Officer
Joseph Farmer JD
President & Chief Operating Officer
Jennifer Fox
Chief Financial Officer & Chief Business Officer
Caroline Chevalier
Chief Human Resources Officer
Tanya Fischer
Chief Medical Officer & Head of Research and Development

Board

Hongbo Lu Ph.D
Vivo Capital
Jake Nunn
SR One Capital Management
James Boylan
Enavate Sciences
Marietta Wu Ph.D
Quan Capital
Patrick Enright
Longitude Capital

Zenas BioPharma News and Media Highlights

Zenas, with new funding, aims dual-targeting antibody at lupus and MS

In a series C funding round, Zenas raised $200 million from investors.
Browse Insights
Other Companies Like Zenas BioPharma in the BioTech & Pharma Sector
Sector: Healthcare
Subsector: BioTech & Pharma
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
Affinia TherapeuticsAffinia Therapeutics----$xx.xxSeries B$365.7MM$xx.xx$110MM
Altos LabsAltos Labs----$xx.xxSeries C$6.33B$xx.xx$1.5B
ArsenalBioArsenalBio----$xx.xxSeries C$1.66B$xx.xx$327.5MM
Colossal BiosciencesColossal Biosciences----$xx.xxSeries C$10.2B$xx.xx$200MM
EgenesisEgenesis----$xx.xxSeries D$332.59MM$xx.xx$90.96MM
Isomorphic LabsIsomorphic Labs----$xx.xx--------
LoyalLoyal----$xx.xxSeries B-5$428.44MM$xx.xx$17.49MM
OwkinOwkin----$xx.xxSeries B-1$1.46B$xx.xx$50MM
Precision NeurosciencePrecision Neuroscience----$xx.xxSeries C$542.69MM$xx.xx$102MM
Xaira TherapeuticsXaira Therapeutics----$xx.xxSeries A$2.65B$xx.xx$500MM

Updated on: Jan 22, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.